1. Herpes zoster in immunocompromised patients: Incidence, timing, and risk factors 
Peter K. Wung, MD, Janet T. Holbrook, PhD, MPH, Gary S. Hoffman, MD, Andrea K. Tibbs, BS, Ulrich Specks, MD, Y.-I. Min, PhD, Peter A. Merkel, MD, MPH, Robert Spiera, MD, John C. Davis, MD, MPH, E. William St. Clair, MD, Joseph McCune, MD, Steven R. Ytterberg, MD, Nancy B. Allen, MD, John H. Stone, MD, MPH 
The American Journal of Medicine 
Volume 118, Issue 12, Pages 1416.e e18 (December 2005)
DOI: /j.amjmed
Copyright © 2005 Elsevier Inc. Terms and Conditions

2. Figure
Timing of herpes zoster (HZ) in relation to randomization. Kaplan-Meier curve of herpes zoster events in the Wegener’s Granulomatosis Etanercept Trial. The first 6 months after randomization corresponded to the period of the most intensive immunosuppression for this cohort.
The American Journal of Medicine  , 1416.e e18DOI: ( /j.amjmed )
Copyright © 2005 Elsevier Inc. Terms and Conditions